6.5
Agonistas adrenérgicos: Agentes de Ação Direta
Medicamentos que mimetizam a ação de catecolaminas endógenas como noradrenalina e adrenalina são chamados de agonistas adrenérgicos ou simpaticomiméti…
As catecolaminas endógenas polares são potentes estimulantes dos receptores adrenérgicos. No entanto, eles são não seletivos e ineficazes por via oral devido à inativação por enzimas metabólicas.
Agonistas adrenérgicos ou simpatomiméticos são drogas sintéticas com melhor biodisponibilidade que provocam uma resposta simpática direta, indireta ou por ação mista.
Os simpatomiméticos de ação direta atuam nos adrenoceptores pós-sinápticos sem interferir no neurônio pré-sináptico.
Eles são classificados como agentes seletivos ou não seletivos com base em seletividade considerável, parcial ou nenhuma seletividade para um subtipo específico de receptor adrenérgico.
Agonistas não seletivos de ação direta, como oximetazolina - um descongestionante e isoprenalina não possuem seletividade de subtipo.
Agentes seletivos de ação direta geram uma resposta terapêutica com base no tipo de receptor adrenérgico alvo.
Por exemplo, agonistas seletivos ɑ1- e ɑ2- como fenilefrina e clonidina, respectivamente, têm ações cardiovasculares.
ꞵ Agonistasseletivos 1 como a dobutamina aumentam o débito cardíaco, enquanto ꞵ agonistasseletivos 2 como a terbutalina são usados para tratar a asma.
View the full transcript and gain access to JoVE Core videos
Q1: What are direct-acting adrenergic agonists and how do they differ from endogenous catecholamines?
Direct-acting adrenergic agonists, or sympathomimetics, are synthetic drugs that mimic endogenous catecholamines like noradrenaline and adrenaline. Unlike polar endogenous catecholamines, which are nonselective and orally ineffective due to metabolic enzyme inactivation, direct-acting agonists have better bioavailability and act on postsynaptic adrenoceptors without interfering with presynaptic neurons.
Q2: How are direct-acting sympathomimetics classified based on receptor selectivity?
Direct-acting sympathomimetics are classified as selective or nonselective agents based on their adrenoceptor subtype selectivity. Nonselective agents like oxymetazoline and isoprenaline possess no subtype selectivity. Selective agents target specific adrenoceptor types—α1, α2, β1, β2, or β3—generating therapeutic responses based on the targeted receptor, avoiding unwanted side effects.
Q3: What are the cardiovascular effects of alpha-selective direct-acting agonists?
Alpha-selective agonists produce distinct cardiovascular actions based on their subtype. α1-selective agonists like phenylephrine enhance cardiovascular function, while α2-selective agonists like clonidine inhibit cardiovascular responses. These agents activate specific alpha-adrenoceptor subtypes on vascular and cardiac tissues to produce their targeted hemodynamic effects.
Q4: How do beta-1 and beta-2 selective agonists differ in their therapeutic applications?
β1-selective agonists like dobutamine increase heart rate and cardiac output, making them useful for cardiac support. β2-selective agonists like terbutaline and salbutamol act as bronchodilators and uterine relaxants, treating asthma and other respiratory conditions. Each targets distinct beta-adrenoceptor subtypes to achieve specific therapeutic outcomes.
Q5: What is the mechanism by which direct-acting agonists remain effective despite neuronal catecholamine depletion?
Direct-acting adrenergic agonists activate adrenoceptors independently of presynaptic neurons, making them unaffected by neuronal catecholamine-depleting agents like reserpine and guanethidine. This independence from presynaptic function allows direct-acting agonists to maintain their therapeutic efficacy even when endogenous neurotransmitter stores are depleted.
Q6: What role do beta-3 selective agonists play in treating urinary dysfunction?
β3-selective agonists like mirabegron treat urinary incontinence by acting on the detrusor muscle of the bladder. These agents activate β3-adrenoceptors on bladder smooth muscle, promoting relaxation and increasing bladder capacity. This selective mechanism allows targeted treatment of overactive bladder without affecting cardiac or respiratory function.
Q7: Why do direct-acting sympathomimetics have better oral bioavailability than endogenous catecholamines?
Endogenous catecholamines are polar molecules rapidly inactivated by metabolic enzymes, rendering them orally ineffective. Synthetic direct-acting sympathomimetics are chemically modified to resist enzymatic degradation and improve absorption, providing better bioavailability. This structural advantage allows oral administration and sustained therapeutic effects compared to natural catecholamines.